At a glance
A combined research record involving amylin-related and GLP-1 receptor activity.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together amylin-related and GLP-1 receptor activity. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[4][5][1]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[2][1][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cagrilintide + Semaglutide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Titration (3 mL = ~3.33 mg/mL total)
| Week/Phase | Dose per Peptide (mcg / mg) | Units (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) each | 15 units (0.15 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) each | 30 units (0.30 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) each | 60 units (0.60 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg (2.4 mg) each | 144 units (1.44 mL) |
Route: Subcutaneous injection. Frequency: Once weekly[1][3]. Note: Each dose delivers equivalent amounts of both cagrilintide and Semaglutide (e.g., 0.25 mg cagrilintide + 0.25 mg Semaglutide at Week 1). The 2.4 mg target mirrors clinical trial protocols[1][2].
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support significant weight reduction through dual amylin + GLP‑1 receptor agonism[1][2].
- Schedule: Weekly subcutaneous injections for 16+ weeks (maintenance thereafter).
- Dose Range: 0.25–2.4 mg each peptide weekly with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days.
Suggested weekly titration approach.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 30 days[7].
Storage Instructions
Proper storage preserves peptide quality[7].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7][8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6].
- For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week weekly protocol with gradual titration.
-
Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each):
- 8 weeks ≈ 1 vial (~6 mg total used)
- 12 weeks ≈ 2 vials (~14 mg total used)
- 16 weeks ≈ 3 vials (~27.6 mg total used)
-
Insulin Syringes (U‑100):
- Per week: 1 syringe (once weekly)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
Public health resource
StatPearls (2025) — Semaglutide: pharmacology, indications, and clinical use overview (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
Cureus (2024) — Semaglutide: risks and benefits review (PMC) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Public health resource
WHO (2010) — Best practices for injection and related procedures (WHO toolkit) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Source document
LibreTexts (2020) — Intradermal and subcutaneous injections: clinical procedures (opens in a new tab)med.libretexts.org
Back to overview ↑ - 08
Public health resource
CDC (2024) — Vaccine administration: subcutaneous injection technique (opens in a new tab)www.cdc.gov
Back to overview ↑ - 09
Research publication
PubMed (2024) — Cagrilintide‑Semaglutide in adults with overweight/obesity and type 2 diabetes (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Source document
ScienceDirect (2024) — Efficacy and safety of CagriSema 2.4 mg + 2.4 mg in type 2 diabetes (opens in a new tab)www.sciencedirect.com
Back to overview ↑ - 11
Research publication
PMC (2019) — Subcutaneous drug injection: pharmacologic review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.